Cutamesine激活Sigma-1受体通过抑制内质网应激和线粒体功能障碍减轻窒息性心脏骤停大鼠模型神经元凋亡
研究采用大鼠窒息性心脏骤停模型,复苏后存活大鼠随机分为三组(每组18只):心肺复苏组(0.9%氯化钠1 mL/kg)、SA4503低剂量组(1 mg/kg)和高剂量组(2.5 mg/kg)。SA4503治疗组神经功能结局优于心肺复苏组,caspase-3及内质网应激标志物C/EBP同源蛋白和caspase-12蛋白水平较低,线粒体膜电位、组织ATP浓度、细胞内钙超载恢复正常,Sigma-1受体蛋白水平上调。高剂量组较低剂量组显示出显著脑保护作用,疗效呈剂量依赖性。作者结论认为,心脏骤停下调Sigma-1受体蛋白表达,SA4503激活Sigma-1受体通过减轻内质网应激和线粒体功能障碍、最终抑制神经元凋亡而发挥全脑缺血/再灌注损伤保护作用。
要点
- 大鼠窒息性心脏骤停复苏后,SA4503 1 mg/kg和2.5 mg/kg组神经功能结局均优于心肺复苏组(0.9%氯化钠1 mL/kg)。
- SA4503高剂量(2.5 mg/kg)较低剂量(1 mg/kg)显示出显著脑保护作用,疗效呈剂量依赖性。
- SA4503治疗组caspase-3及内质网应激标志物C/EBP同源蛋白、caspase-12蛋白水平低于心肺复苏组。
- SA4503治疗组线粒体膜电位、组织ATP浓度、细胞内钙超载恢复正常,Sigma-1受体蛋白水平上调。
- 作者结论:心脏骤停下调Sigma-1受体蛋白表达,SA4503通过减轻内质网应激和线粒体功能障碍抑制神经元凋亡。
适用人群与场景
- 大鼠窒息性心脏骤停复苏后存活模型,用于研究全脑缺血/再灌注损伤的脑保护作用及机制。
处置流程与药物剂量
- 复苏后存活大鼠随机分为三组(每组18只):心肺复苏组给予0.9%氯化钠1 mL/kg;SA4503低剂量组给予1 mg/kg SA4503;SA4503高剂量组给予2.5 mg/kg SA4503。
研究设计与关键结果
- 研究类型为大鼠窒息性心脏骤停模型实验,复苏后存活大鼠随机分为三组,每组18只。
- SA4503治疗组神经功能结局优于心肺复苏组。
- SA4503治疗组caspase-3及内质网应激标志物C/EBP同源蛋白和caspase-12蛋白水平低于心肺复苏组。
- SA4503治疗组线粒体膜电位、组织ATP浓度、细胞内钙超载恢复正常,Sigma-1受体蛋白水平较心肺复苏组上调。
- SA4503高剂量(2.5 mg/kg)较低剂量(1 mg/kg)显示出显著脑保护作用,疗效呈剂量依赖性。
证据类型、等级与局限
- 证据类型:大鼠窒息性心脏骤停模型动物实验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者结论认为,心脏骤停下调Sigma-1受体蛋白表达,SA4503激活Sigma-1受体通过减轻内质网应激和线粒体功能障碍、最终抑制神经元凋亡,对窒息性心脏骤停大鼠模型的全脑缺血/再灌注损伤发挥保护作用;该结论来自大鼠模型,原文未据此给出临床推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Global cerebral ischemic/reperfusion (I/R) injury after cardiac arrest (CA) is a major cause of mortality and morbidity in survivors of resuscitation. We utilized a rat model of asphyxia CA to explore the functional effects and mechanisms of Sigma-1 receptor (Sig-1R) activation in cerebral protection using the Sig-1R agonist cutamesine (SA-4503).
METHODS: After resuscitation, the surviving rats were randomly divided into three groups (n = 18 each): the cardiopulmonary resuscitation (CPR) group (0.9% saline at 1 mL/kg); the SA4503 low-dose group (1 mg/kg SA4503); and the SA4503 high-dose group (2.5 mg/kg SA4503). The neurological deficit scores were recorded, and the cerebral cortex was harvested for western blotting. Mitochondrial transmembrane potential, adenosine triphosphate (ATP) concentrations, calcium homeostasis, and mitochondrial ultrastructure were also studied.
RESULTS: The SA4503 treatment groups exhibited improved neurological outcomes compared with the CPR group. The protein levels of caspase-3 and the endoplasmic reticulum stress markers C/EBP homologous protein and caspase-12 were lower in the SA4503 treatment groups compared with the CPR group. SA4503 treatment also normalized mitochondrial membrane potential, tissue ATP concentrations, intracellular Ca overload, and upregulated Sig-1R protein level compared with the CPR group. The SA4503 high dose treatment showed significant cerebral protective effects compared with the SA4503 low dose treatment. The therapeutic effect of SA4503 was dose-dependent.
CONCLUSIONS: CA downregulated Sig-1R protein expression. Activating Sig-1R using SA4503 protected against global cerebral I/R injury in a rat model of asphyxia CA by alleviating endoplasmic reticulum stress and mitochondrial dysfunction and eventually inhibiting neuronal apoptosis.
参考来源
- Qin J, Wang P, Li Y, et al. Activation of Sigma-1 Receptor by Cutamesine Attenuates Neuronal Apoptosis by Inhibiting Endoplasmic Reticulum Stress and Mitochondrial Dysfunction in a Rat Model of Asphyxia Cardiac Arrest. Shock. 2019. PMID: 29424796. doi:10.1097/SHK.0000000000001119
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。